Clinical Policy: Paliperidone Long-Acting Injections (Invega Sustenna, Invega Trinza)
Reference Number: CP.PHAR.291
Effective Date: 12.01.16
Last Review Date: 08.18
Line of Business: Medicaid

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Paliperidone (Invega Sustenna®, Invega Trinza®) is an atypical antipsychotic.

FDA Approved Indication(s)
Invega Sustenna is indicated:
• For the treatment of schizophrenia in adults
• For the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

Invega Trinza is indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invega Sustenna (1-month paliperidone palmitate extended-release injectable suspension) for at least four months.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Invega Sustenna and Invega Trinza are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Schizophrenia (must meet all):
      1. Diagnosis of schizophrenia;
      2. Prescribed by or in consultation with a psychiatrist;
      3. Age ≥ 18 years;
      4. One of the following (a or b):
         a. If Invega Sustenna is requested, meets (i or ii):
            i. Established tolerability with long-acting risperidone injection (Risperdal Consta®);
            ii. Established tolerability with oral paliperidone or risperidone (preferred agent) AND has a history of non-adherence to oral antipsychotic therapy (see Appendix D for examples);
         b. If Invega Trinza is requested, adequate treatment has been established with Invega Sustenna for ≥ 4 months;
      5. Dose does not exceed (a or b):
         a. Invega Sustenna: 234 mg per month;
b. Invega Trinza: 819 mg every 3 months. 

**Approval duration: 6 months**

**B. Schizoaffective Disorder (must meet all):**
1. Diagnosis of schizoaffective disorder;
2. Request is for Invenga Sustenna;
3. Prescribed by or in consultation with a psychiatrist;
4. Age $\geq$ 18 years;
5. History of non-adherence to oral antipsychotic therapy (*see Appendix D for examples*);
6. Established tolerability with oral paliperidone or risperidone (preferred agent);
7. Dose does not exceed 234 mg per month.

**Approval duration: 6 months**

**C. Other diagnoses/indications**
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Invenga Sustenna for schizophrenia or schizoaffective disorder, or Invega Trinza for schizophrenia, and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed the following (a or b):
   a. Invega Sustenna: 234 mg per month;
   b. Invega Trinza: 819 mg every 3 months.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

**A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents;**

**B. Dementia-related psychosis.**
CLINICAL POLICY
Paliperidone Long-Acting Injections

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| Paliperidone (Invega®)    | Schizophrenia and schizoaffective  
                           | Adults: initially, 6 mg PO QD  
                           | Recommended dose: 3-12 mg/day | 12 mg/day |
| Risperidone (Risperdal®)  | Schizophrenia  
                           | Adults: initially, 2 mg/day PO (as a single dose) or 1 mg PO BID; adjust as tolerated to the recommended target dose of 4 to 8 mg/day  
                           | Effective dose range: 4 to 16 mg/day | 16 mg/day |
| Risperdal Consta (risperidone) | Schizophrenia  
                           | Adults: 25 mg IM (deep gluteal or deltoid injection) once every 2 weeks; some adult patients not responding to the 25 mg dose may benefit from 37.5 mg or 50 mg IM once every 2 weeks | 50 mg every 2 weeks |
| Invega Sustenna (paliperidone) | See Section V Dosage and Administration | See Section V Dosage and Administration |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications
Not applicable

Appendix D: Examples of Oral Antipsychotics – Generic (Brand)

<table>
<thead>
<tr>
<th>Typical/First Generation Antipsychotics†</th>
<th>Atypical/Second Generation Antipsychotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpromazine (Thorazine®)</td>
<td>Aripiprazole (Abilify®)*</td>
</tr>
<tr>
<td>Fluphenazine (Prolixin®)</td>
<td>Asenapine maleate (Saphris®)</td>
</tr>
<tr>
<td>Haloperidol (Haldol®)</td>
<td>Brexiprazole (Rexulti®)</td>
</tr>
<tr>
<td>Loxapine (Loxitane®)</td>
<td>Cariprazine (Vraylar®)</td>
</tr>
<tr>
<td>Perphenazine (Trilafon®)</td>
<td>Clozapine (Clozaril®)</td>
</tr>
<tr>
<td>Pimozide (Orap®)</td>
<td>Iloperidone (Fanapt®)</td>
</tr>
<tr>
<td>Thoridazine (Mellaril®)</td>
<td>Lurasidone (Latuda®)</td>
</tr>
<tr>
<td>Thiothixene (Navane®)</td>
<td>Olanzapine (Zyprexa®)*</td>
</tr>
<tr>
<td>Trifluoperazine (Stelazine®)</td>
<td>Olanzapine/Fluoxetine (Symbyax®)</td>
</tr>
</tbody>
</table>
## V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paliperidone (Invega Sustenna)</td>
<td>Schizophrenia</td>
<td>Initial: 234 mg IM on day 1 and 156 mg one week later (day 8), both administered in the deltoid muscle Maintenance*: 39-234 mg IM monthly in either the deltoid or gluteal muscle</td>
<td>234 mg/month</td>
</tr>
<tr>
<td></td>
<td>Schizoaffective disorder</td>
<td>Initial: 234 mg IM on day 1 and 156 mg one week later (day 8), both administered in the deltoid muscle Maintenance*: 78-234 mg IM monthly in either the deltoid or gluteal muscle</td>
<td>234 mg/month</td>
</tr>
<tr>
<td>Paliperidone (Invega Trinza)</td>
<td>Schizophrenia</td>
<td>Invega Trinza is to be used only after Invega Sustenna® (1-month paliperidone palmitate extended-release injectable suspension) has been established as adequate treatment for at least four months. Initiate Invega Trinza when the next 1-month paliperidone palmitate dose is scheduled with an Invega Trinza dose based on the previous 1-month injection dose, using the equivalent 3.5-fold higher dose as shown: Last Invega Sustenna dose: Invega Trinza dose to initiate 78 mg: 273 mg 117 mg: 410 mg 156 mg: 546 mg 234 mg: 819 mg Following the initial Invega dose, Invega Trinza should be administered IM every 3 months. Invega Trinza</td>
<td>819 mg every 3 months</td>
</tr>
</tbody>
</table>

†Most typical/first generation antipsychotics are available only as generics in the U.S.  
*Long-acting injectable formulation available
Paliperidone Long-Acting Injections

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paliperidone (Invega Sustenna)</td>
<td>may be administered up to 7 days before or after the monthly time point of the next scheduled paliperidone palmitate 1-month dose.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Administered 5 weeks after the first injection

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paliperidone (Invega Sustenna)</td>
<td>Extended-release injectable suspension: 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg</td>
</tr>
<tr>
<td>Paliperidone (Invega Trinza)</td>
<td>Extended-release injectable suspension: 273 mg, 410 mg, 546 mg, or 819 mg</td>
</tr>
</tbody>
</table>

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.122.LAI Antipsychotics and converted to new template. Age removed and max dose added. Added Risperdal Consta to Invega Sustenna tolerability statement per PI. Hypersensitivity contraindication added. Appendix B: Oral Antipsychotics – reviewed, edited and updated per UpToDate and FDA websites (6-8). Specialist review by psychiatrist.</td>
<td>11.16</td>
<td>12.16</td>
</tr>
<tr>
<td>Converted to new template. Added age restriction per PI. Removed requirements related to hypersensitivity to either paliperidone or risperidone and history of dementia-related psychosis per safety approach. Removed “therapeutic plan includes initial concomitant use of oral antipsychotic therapy as appropriate” since requirement is subjective and specialist is involved in care. Increased initial approval duration from 3 to 6 months. Re-auth: combined criteria sets and updated to allow continuation of therapy for schizophrenia and schizoaffective disorder. Added dementia-related psychosis under section III.</td>
<td>07.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: no significant changes;; references reviewed and updated.</td>
<td>05.01.18</td>
<td>08.18</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.
Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.